Literature DB >> 1499372

Treatment of severe Mooren's ulcer with cyclosporin A eyedrops.

J C Zhao1, X Y Jin.   

Abstract

Sixteen patients (21 eyes) with severe, progressive Mooren's ulcer, unresponsive to medical or surgical therapy, were treated with 0.5% cyclosporin A (CsA) eyedrops. Only 18 eyes were included in this study. Fifteen eyes showed marked effects within the first 12 days. Eleven eyes completely healed, on the average, in 1.3 months without side-effects. Follow-up for 24-31 months showed no recurrence. The whole-blood level of CsA determined randomly by high-pressure liquid chromatography in 7 patients was 28.95 micrograms/L on the average. It is concluded that autoimmunological mechanism plays an important part in pathogenesis of Mooren's ulcer, and the efficacy of topical CsA is attributable to its effect of local depression of ocular immunopathological reactions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1499372

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  2 in total

1.  Upregulation of NLRP3 inflammasome components in Mooren's ulcer.

Authors:  Zhiyuan Li; Chao Wei; Shuang Wang; Ting Liu; Hualei Zhai; Weiyun Shi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-28       Impact factor: 3.117

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.